Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

ConditionNodal Marginal Zone Lymphoma

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorInternational Extranodal Lymphoma Study Group (IELSG)

About this trial

International retrospective observational cohort study aimed to describe a molecular classification for NMZL.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Male or female adults 18 years or older

Diagnosis of NMZL on lymph node histology after Jan 1st, 2000

Availability of tumor material from lymph node (either frozen or FFPE) collected when the patient was treatment naïve

Availability of the baseline and follow-up annotations

Disqualifiers

None

Trial population

Patients with diagnosis of NMZL on lymph node histology

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

Define and quantify molecular subsets.

Time frame

Two years: from the end of samples collection to the end of study analysis

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

International Extranodal Lymphoma Study Group (IELSG)

Lead sponsor

Source ClinicalTrials.gov

Apply now